On July 6, 2026, a trial update was recorded for the study registered as NCT04020055, associated with larazotide in this dataset. The trial is titled "A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease." It is listed as Phase 3 and its current status is active, not recruiting.
The registry entry does not include any additional detail on enrollment numbers, outcomes, or interim data. No results have been posted as part of this status update. The record simply confirms that the trial continues under its current phase without new participant recruitment at this time.
As an active, not recruiting Phase 3 study, this designation indicates that participant enrollment has closed while the trial proceeds through its planned phases. No efficacy or safety conclusions can be drawn from a status update alone. This entry reflects only the administrative state of the trial as of the listed date.
Readers interested in background on larazotide can consult the compound overview for further context.